FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Until now, H1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response. (Source: Roche Media News)
Source: Roche Media News - March 24, 2014 Category: Pharmaceuticals Source Type: news
FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Until now, H1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response. (Source: Roche Investor Update)
Source: Roche Investor Update - March 24, 2014 Category: Pharmaceuticals Source Type: news
FDA OKs Omalizumab (Xolair) for Chronic HivesFDA OKs Omalizumab (Xolair) for Chronic Hives
Omalizumab is indicated for people aged 12 years or older with chronic idiopathic urticaria who fail to find relief with antihistamines. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Alert Source Type: news
FDA Approves Xolair for Chronic Hives
(MedPage Today) -- The FDA has approved omalizumab (Xolair) for treatment of chronic idiopathic urticaria, drugmaker Genentech announced. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 21, 2014 Category: Primary Care Source Type: news
Omalizumab Appears to Improve Oral ImmunotherapyOmalizumab Appears to Improve Oral Immunotherapy
Omalizumab can increase the benefits of oral immunotherapy for milk allergy and reduce the adverse effects, a new study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
New indication for Xolair approved by the European Commission for treatment in chronic spontaneous urticaria patients
Novartis has announced that the European Commission (EC) has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients, who do not respond to the current mainstay of therapy, H1 antihistamines. The approved dose in CSU is 300 mg administered by subcutaneous injection once every four weeks. Prescribers are advised to periodically reassess the need for continued therapy. Clinical trial experience of treatment beyond six months in this indication is limited. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 10, 2014 Category: Consumer Health News Tags: Dermatology Source Type: news
Novartis' Urticaria drug Xolair obtains EU approval
Novartis has received approval from the European Commission (EC) to use Xolair (omalizumab) as an add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to H1-antihista… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 10, 2014 Category: Pharmaceuticals Source Type: news
Xolair Makes Milk Allergy Tx More Tolerable
SAN DIEGO (MedPage Today) -- Giving omalizumab (Xolair) around the start of oral immunotherapy for milk allergy improved safety, a randomized trial confirmed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 5, 2014 Category: Pediatrics Source Type: news
Asthma Drug Helps Desensitize Multiple Food Allergies Faster in Early Studies (FREE)
By Kelly Young
An early trial suggests that the monoclonal antibody omalizumab can speed up oral immunotherapy in patients with multiple food allergies. Results of the phase 1 safety trial were published in Allergy, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 3, 2014 Category: Primary Care Source Type: news
Rapid Multi-Food Allergy Tx Feasible With Anti-IgE Drug
(MedPage Today) -- Multiple food allergies could be tackled at the same time in a rapid oral immunotherapy regimen together with omalizumab (Xolair), a proof-of-concept study showed. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 1, 2014 Category: Allergy & Immunology Source Type: news
Omalizumab Aids Desensitization to Several Food AllergiesOmalizumab Aids Desensitization to Several Food Allergies
People with multiple food allergies could be safely desensitized to them using simultaneous oral immunotherapy; the asthma drug omalizumab could shorten this process. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Oral immunotherapy with antibody-based medication could be used to treat multiple food allergies
By combining standard desensitization of up to five food allergies with antibody-based medication omalizumab, it may be possible to treat multiple food allergies in a shorter timeframe. This is according to a Phase 1 trial, with 25 patients, published in open access journal Allergy, Asthma & Clinical Immunology. Food allergies affect up to 8% of children in the US, and 30% of those affected have more than one allergy. It has been estimated that food allergies cost US$25 billion each year, with approximately US$20 million borne by patients' families. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 27, 2014 Category: Consumer Health News Tags: Allergy Source Type: news
Positive opinion from CHMP for Xolair®
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. The recommended dose is 300mg by subcutaneous injection every four weeks. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 11, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Dermatology Latest News Source Type: news
Omalizumab Retreatment Effective in Chronic UrticariaOmalizumab Retreatment Effective in Chronic Urticaria
Patients with recurrent urticaria after omalizumab discontinuation can benefit from retreatment, according to German researchers. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 10, 2014 Category: Dermatology Tags: Dermatology News Source Type: news
EU Regulators Recommend Xolair for HivesEU Regulators Recommend Xolair for Hives
Regulators in the European Union recommended extending the indication of omalizumab, already approved for allergic asthma, to chronic spontaneous urticaria. International Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 27, 2014 Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news
